Clin2
NCT07756736Possibly a fitNot yet recruiting

Psilocybin therapy for HIV and meth use

Methamphetamine Use DisorderHuman Immunodeficiency Virus (HIV)

Treatments studied

Part of Immune system & allergy, Infections, Mental health clinical trials.

This study tests whether a drug called psilocybin (a psychedelic) can help people with HIV stop using methamphetamine. If you want to quit meth and are living with HIV, this trial might offer a new approach.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
25 years to 64 years
Study type
Interventional

Who can take part

  • You are between 25 and 64 years old.
  • You have been living with HIV for at least 3 months.
  • You use methamphetamine regularly and want to quit.
  • You are willing to stop using meth and other non-prescribed drugs for at least 24 hours before and during the treatment sessions.
  • You have stable housing and a cellphone.
  • You do not have serious mental health conditions like schizophrenia or bipolar I disorder.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07774702Not yet recruiting· Phase 2
Psilocybin for methamphetamine use disorder

This trial tests whether a psychedelic drug called psilocybin can help people cut down or stop using methamphetamine. You'll take the drug in a supervised setting and get support to aim for full abstinence.

Birmingham, Alabama
NCT06899594Recruiting· Early Phase 1
Psilocybin for quitting methamphetamine

This trial tests whether psilocybin (a psychedelic medicine) can help people quit methamphetamine. You'll receive counseling before, during, and after the drug session, and your progress will be followed for several months.

Shreveport, Louisiana
NCT07584369Not yet recruiting· Phase 4
How methamphetamine affects HIV in stable patients

This study gives HIV-positive people who are doing well on HIV medication a small dose of methamphetamine to see how it affects their virus and immune system. Researchers want to understand if methamphetamine can wake up hidden HIV that's not being detected.

San Francisco, California
NCT06666010Not yet recruiting· Phase 2
Psilocybin-assisted therapy for stimulant use disorder

This trial tests whether a single dose of psilocybin (PEX010) combined with therapy can help people stop using methamphetamine or other stimulants. It focuses on safety and early signs of effectiveness.

NCT06444243Not yet recruiting· Phase 2
Psilocybin therapy for alcohol use disorder

This trial tests whether a psilocybin (magic mushroom) therapy session can help people with alcohol use disorder reduce their drinking. You'll have one or two guided sessions with a therapist, plus support before and after, to see if it helps you change your drinking habits.

NCT06660381Recruiting· Phase 1
Psilocybin therapy for cannabis use disorder

This study tests if psilocybin (a substance that can change how you think and feel) can help people reduce or stop using cannabis. You will receive support and be monitored closely throughout the trial.

Baltimore, Maryland

Hear when a new Methamphetamine Use Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.